SofPort lenses win NTIOL status

Article

Bausch & Lomb has received new technology intraocular lens (NTIOL) status for the regular and violet-filtering models of its SofPort Advanced Optics intraocular lenses (IOLs).

Bausch & Lomb has received new technology intraocular lens (NTIOL) status for the regular and violet-filtering models of its SofPort Advanced Optics intraocular lenses (IOLs).

The Centers for Medicare and Medicaid Services (CMS) in the US has increased the current reimbursements for both lenses by $50. Only ASC-based surgeons are entitled to this additional reimbursement, however, this does represent a large portion of the cataract procedures performed in the US.

According to Bausch & Lomb, this new reimbursement will cover the entire cost of the IOLs, which means that patients will no longer have to pay for any additional costs.

Bausch & Lomb's SofPort lenses, which feature an aberration-free design, were able to demonstrate clinical benefit at least equal to the Tecnis IOL (Advanced Medical Optics), which established the NTIOL subset for aberration reduction.

The increased reimbursements will remain in effect until February 26, 2011.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.